Real, messy hope delivered to your inbox daily, from Good Good Good.
Good headlines...
🌎 With the Trump administration failing to send a representative, California Governor Gavin Newsom attended COP30 to represent the U.S., sign major deals, and project his state — one of the largest economies in the world — as a dependable clean-tech partner.
✈️ A group of 17 transgender members of the U.S. Air Force is suing the U.S. government over the military’s unlawful revocation of their early retirement pensions and benefits.
Global health
Photo courtesy of Novartis
Scientists unveiled a new, effective anti-malaria drug to help fight rising drug resistance
Drugmaker Novartis and the nonprofit Medicines for Malaria Venture unveiled a new antimalarial drug that’s as effective as existing treatments — but could help address rising resistance to those treatments.
Called GanLum, the drug was more than 97% effective at treating malaria in the final-stage trial results. While existing treatments work against malaria, there has been growing resistance to one of the key drugs used.
This new treatment option is the first major advancement in treating malaria in decades, and it works differently from previous antimalarial drugs.
Why is this good news? Malaria still kills more than 600,000 people annually, most of them children under five years old in sub-Saharan Africa. If drug resistance were to continue rising without a new treatment option, it would leave health care providers globally without another option.
Rapid expansion of renewable energy has put the world way ahead of the curve to triple capacity by 2030
At COP28 in 2023, over 130 governments pledged to triple the world’s existing renewable energy capacity to 11 terawatts by 2030 — since then, deployment has skyrocketed.
To achieve a tripling, renewables additions needed to increase by 21% every year, but additions have actually averaged 29% annually from 2023 to 2025.
As a result, the world is already way ahead of the curve to achieve triple capacity — additions would only need to rise by 12% annually to still achieve it.
Need help? Contact us for assistance. We’ve got your back.
You received this email because you signed up for the Goodnewsletter from Good Good Good — or because you followed a recommendation from another newsletter or ordered a Goodnewspaper.
To stop receiving The Goodnewsletter, unsubscribe. To opt in or out of other emails from Good Good Good, manage your email settings. To stop receiving all emails from Good Good Good — which may potentially include paid subscriber-exclusive content — you can opt out entirely.